Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

This study has been completed.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Weill Medical College of Cornell University Identifier:
First received: October 9, 2006
Last updated: December 13, 2012
Last verified: December 2012
Results First Received: October 12, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Carcinoma, Non-small Cell Lung
Intervention: Drug: Tarceva (Erlotinib)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The recruitment period was from 10/13/06 to 10/8/08. Patients were recruited from the Weill Cornell Medical College Thoracic Surgery outpatient office.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Erlotinib Erlotinib 150 mg po daily.

Participant Flow:   Overall Study

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Erlotinib Erlotinib 150 mg po daily

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Median (Full Range)
 (56 to 82) 
[Units: Participants]
Female   11 
Male   11 
Region of Enrollment 
[Units: Participants]
United States   22 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Response Rate Defined as the Percentage of Subjects Achieving at Least 50% Tumor Volume Reduction.   [ Time Frame: High resolution CT scans for response assessment will be obtained after 3 weeks of treatment with Tarceva®. ]

2.  Primary:   Safety of Tarceva in the Neoadjuvant Setting   [ Time Frame: From the onset of the AE until 30 days after the last study drug dose, until recovery is noted, or until the Investigator determines the patient's condition is stable. ]

3.  Secondary:   Time-to-progression and Disease-free Survival.   [ Time Frame: Every 3 months for the first 6 months, then yearly for 2 years. ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Safety   [ Time Frame: Day 1 of treatment to 2 years. ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Nasser Altorki, MD
Organization: Weill Cornell Medical College
phone: 212-746-5156

Responsible Party: Weill Medical College of Cornell University Identifier: NCT00385996     History of Changes
Other Study ID Numbers: OSI TAR 728
Study First Received: October 9, 2006
Results First Received: October 12, 2012
Last Updated: December 13, 2012